ATOS FY2024 EPS Forecast Raised by Cantor Fitzgerald

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities researchers at Cantor Fitzgerald lifted their FY2024 EPS estimates for Atossa Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of ($0.20) per share for the year, up from their prior estimate of ($0.22). The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.21) per share.

ATOS has been the subject of several other research reports. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright upped their target price on Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday.

Atossa Therapeutics Price Performance

Atossa Therapeutics stock opened at $1.28 on Monday. The stock has a market cap of $161.03 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. The firm has a 50-day moving average of $1.44 and a two-hundred day moving average of $1.37. Atossa Therapeutics has a 1 year low of $0.67 and a 1 year high of $2.31.

Institutional Trading of Atossa Therapeutics

A number of hedge funds have recently bought and sold shares of ATOS. XTX Topco Ltd bought a new position in shares of Atossa Therapeutics in the 2nd quarter worth $29,000. Intech Investment Management LLC purchased a new position in Atossa Therapeutics in the third quarter valued at about $29,000. SG Americas Securities LLC raised its holdings in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares in the last quarter. Cetera Advisors LLC bought a new position in Atossa Therapeutics in the first quarter worth about $72,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Atossa Therapeutics during the third quarter valued at about $75,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.